Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
66.4M
-
Number of holders
-
202
-
Total 13F shares, excl. options
-
64.9M
-
Shares change
-
-2.94M
-
Total reported value, excl. options
-
$3.63B
-
Value change
-
-$155M
-
Put/Call ratio
-
0.06
-
Number of buys
-
102
-
Number of sells
-
-77
-
Price
-
$55.98
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q4 2024
238 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q4 2024.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 202 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.9M shares
of 66.4M outstanding shares and own 97.77% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (6.95M shares), PRIMECAP MANAGEMENT CO/CA/ (6.57M shares), RA CAPITAL MANAGEMENT, L.P. (6.08M shares), BAKER BROS. ADVISORS LP (6.08M shares), PERCEPTIVE ADVISORS LLC (3.68M shares), VANGUARD GROUP INC (3.44M shares), NEA Management Company, LLC (2.91M shares), Frazier Life Sciences Management, L.P. (1.87M shares), STATE STREET CORP (1.84M shares), and GOLDMAN SACHS GROUP INC (1.81M shares).
This table shows the top 202 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.